| 67.7 0 (0%) | 04-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 83.97 | 1-year : | 98.08 |
| Resists | First : | 71.9 | Second : | 83.97 |
| Pivot price | 66.8  |
|||
| Supports | First : | 64.28 |
Second : | 59.58 |
| MAs | MA(5) : | 68.52 |
MA(20) : | 66.59 |
| MA(100) : | 52.86 |
MA(250) : | 39.34 |
|
| MACD | MACD : | 2.1 |
Signal : | 2.3 |
| %K %D | K(14,3) : | 56.9 |
D(3) : | 64.8 |
| RSI | RSI(14): 58.4 | |||
| 52-week | High : | 71.9 | Low : | 19.46 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CGON ] has closed below upper band by 37.1%. Bollinger Bands are 28.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 69.43 - 69.85 | 69.85 - 70.25 |
| Low: | 65.78 - 66.26 | 66.26 - 66.73 |
| Close: | 66.96 - 67.67 | 67.67 - 68.36 |
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Mon, 13 Apr 2026
New CG Oncology (NASDAQ: CGON) CFO Jim DeTore gets $520k salary, equity - Stock Titan
Thu, 26 Mar 2026
Vanguard realignment reports 0% ownership in CG Oncology (CGON) - Stock Titan
Tue, 17 Mar 2026
CG Oncology, Inc. $CGON Stake Increased by HighVista Strategies LLC - MarketBeat
Tue, 17 Mar 2026
CG Oncology (NASDAQ: CGON) director sells 1,964 shares after option exercises - Stock Titan
Fri, 06 Mar 2026
H.C. Wainwright Raises its Price Target on CG Oncology, Inc. (CGON) to $80 and Maintains a Buy Rating - Yahoo Finance
Tue, 13 Jan 2026
Mulay, James sells CG Oncology (CGON) shares for $584,798 - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 84 (M) |
| Held by Insiders | 6.904e+007 (%) |
| Held by Institutions | 3 (%) |
| Shares Short | 9,500 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.8933e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 97.3 % |
| Return on Equity (ttm) | -15.5 % |
| Qtrly Rev. Growth | 4.04e+006 % |
| Gross Profit (p.s.) | 343.86 |
| Sales Per Share | -18.22 |
| EBITDA (p.s.) | -9.85294e+007 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -132 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -3.72 |
| Price to Cash Flow | 8.63 |
| Dividend | 0 |
| Forward Dividend | 1.055e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|